title: Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.
abstract: Bosentan is a competitive antagonist on endothelin receptor A and B (ETAand ETB), displacing the endogenous binding partner endothelin-1 (ET-1) from its binding sites. After administration of escalating single doses of 10-750 mg as an intravenous (i.v.) infusion, bosentan showed dose-dependent pharmacokinetics (PK). The aim of this analysis was to develop a PK model of bosentan after i.v. administration including competitive antagonism with ET-1 and to analyze its influence on blood pressure and heart rate with a combined pharmacokinetic/pharmacodynamic (PK/PD) model.
  
  
  
  PK/PD data from 70 young male Caucasian subjects were analyzed after single i.v. administration of 10, 50, 250, 500, and 750 mg of bosentan. Population analyses, simulations, and evaluation were performed using a non-linear mixed-effects modeling approach.
  
  
  
  The PK of bosentan was best described by a two-compartment, target-mediated drug disposition (TMDD) model. ET-1 plasma and urine profiles were successfully integrated into the bosentan two-compartment, TMDD model encompassing competition for the same receptor. A multiple-peak phenomenon of bosentan plasma concentrations after i.v. administration was best described by a diurnal expression or reappearance of ET receptors on the cell surface. Blood pressure was best described by an Emaxmodel; heart rate was modeled as a compensatory effect of changes in blood pressure.
  
  
  
  The developed competitive PK/PD model of bosentan and ET-1 after i.v. administration provides a first step towards understanding the complex PK properties of bosentan and offers a valuable tool for future PK/PD research.
authors.affiliation: Clinical Pharmacy, Saarland University, Campus C2 2, 66123, Saarbrücken, Germany.
authors.forename: Anke-Katrin
authors.initials: AK
authors.lastname: Volz
authors.affiliation: Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
authors.forename: Andreas
authors.initials: A
authors.lastname: Krause
authors.affiliation: Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Heidelberg, Germany.
authors.forename: Walter Emil
authors.initials: WE
authors.lastname: Haefeli
authors.affiliation: Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
authors.forename: Jasper
authors.initials: J
authors.lastname: Dingemanse
authors.affiliation: Clinical Pharmacy, Saarland University, Campus C2 2, 66123, Saarbrücken, Germany. thorsten.lehr@mx.uni-saarland.de.
authors.forename: Thorsten
authors.initials: T
authors.lastname: Lehr
mesh_terms: D001794:Blood Pressure / Q000187:drug effects; D000077300:Bosentan; D004305:Dose-Response Relationship, Drug; D065128:Endothelin Receptor Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D019332:Endothelin-1 / Q000378:metabolism*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008954:Models, Biological; D017711:Nonlinear Dynamics; D013449:Sulfonamides / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D055815:Young Adult
chemical_list: D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D013449:Sulfonamides; D000077300:Bosentan